AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02170337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active drug
Study NCT00623337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits
Description: Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
Study NCT03576092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
Study NCT01144923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination treatment
Description: Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
Study NCT02667574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ERIVEDGE
Study NCT04472624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Acute fasting for 72 hours
Study NCT04472624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Intake of a ketogenic diet for 14 days
Study NCT01437215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventana Fenestrated Stent Graft System
Description: Endovascular repair of juxtarenal or pararenal aortic aneurysm
Study NCT04356131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises and massage
Description: Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
Study NCT03032094 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: palatal connective tissue graft to attain root coverage
Study NCT00508807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: 5 mg by mouth (PO) daily for 21 days
Study NCT04855825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Exoskeleton Rehabilitation
Description: Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
Study NCT04855825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Therapy
Description: Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
Study NCT04637789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the whole body vibration
Description: most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
Study NCT04637789 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
Study NCT04637789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
Study NCT01722071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
Study NCT01722071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
Study NCT01266512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
Study NCT01266512 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: 2 Gy per fraction
Study NCT01266512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CISPLATIN
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study NCT03251066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proponent Nasal Spray
Description: The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
Study NCT02632539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual air-impingement operation
Description: A method which we invented to clear subglottic secretion
Study NCT02632539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subglottic secretion drainage
Description: The conventional method which we use subglottic secretion drainage to clear subglottic secretion
Study NCT04348929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
Study NCT04348929 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
Study NCT04080817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neolexon
Description: Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
Study NCT04080817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy
Description: standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
Study NCT04080817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self training
Description: Same frequency \& intensity as in the other interventions
Study NCT04080817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self training
Description: Same frequency \& intensity as in the other interventions
Study NCT01040897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication and Obesity Prevention
Description: Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
Study NCT01040897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Arm
Description: Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
Study NCT01705652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexrutine
Description: Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
Study NCT03524612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: eltrombopag
Description: 12.5, 25, 50 and 75 mg tablets for oral use once daily
Study NCT04690751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate 200Mg Tab Fasted
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Study NCT04690751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate Oral Suspension Fed
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Study NCT04690751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobomate Oral Suspension Fasted
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Study NCT03326258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV
Study NCT03326258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03326258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03326258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03326258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00656474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Administration of Placebo gel on Day 1, 3 and 5 post ablation.
Study NCT00656474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 gel (1.0 %)
Description: Administration on Day 1, 3 and 5 post laser ablation.
Study NCT00751244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Affect Regulation: Guide for Education and Therapy
Description: Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy.
Study NCT03085628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40IU
Study NCT03085628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40IU
Study NCT01425450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1020
Description: Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
Study NCT01425450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF1020 placebo
Description: Single dose: HF1020 placebo capsule
Study NCT03960580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study NCT03960580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study NCT04184414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19-CART
Description: 1-10x106 / kg CD19 CART cells
Study NCT03962257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EngagedMD online learning platform
Description: The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
Study NCT03751358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Erector spinae plane block
Description: Magnetic résonance imaging
Study NCT02022215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 Solution, Low strength
Description: ME1111 Solution, Low strength, applied once daily for 48 weeks
Study NCT02022215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 Solution, High strength
Description: ME1111 Solution, High strength, applied once daily for 48 weeks
Study NCT02022215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Vehicle Solution
Description: Matching Vehicle Solution, applied once daily for 48 weeks
Study NCT00411827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK with conjunctival impression cytology before and after surgery
Study NCT00411827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK with conjunctival impression cytology before and after surgery
Description: LASIK with conjunctival impression cytology before and after surgery
Study NCT01983605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT Suture Delivery Device
Description: LAA exclusion procedure
Study NCT00521599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler
Study NCT00521599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00521599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02557958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
Study NCT02557958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
Study NCT02186652 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole
Study NCT02249299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex Oromucosal Spray
Description: Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
Study NCT02249299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00751244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT) - psychotherapy
Description: Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework.
Study NCT00751244 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-treatment waitlist group
Description: After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
Study NCT03852940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parenteral nutrition
Study NCT03852940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enteral Nutrition
Study NCT01105195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DuraPrep
Description: DuraPrep is used for skin preparation prior to surgery.
Study NCT01105195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: ChloraPrep is used for skin preparation prior to surgery.
Study NCT00531817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Study NCT00531817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Study NCT00531817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Permitted DMARDs
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Study NCT00531817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permitted DMARDs
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Study NCT03855098 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biomarkers of Fruit and Vegetable Intake
Description: Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption.
Study NCT03663725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified protocol
Description: Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
Study NCT03663725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stupp protocol
Description: RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
Study NCT04496154 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)
Description: Triple Strength Omega-3 from Webber Naturals
Study NCT03724084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03724084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT03724084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT03724084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinometostat
Description: Given IV
Study NCT00866047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion
Study NCT01792674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In situ simulation
Study NCT01792674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Off site simulation
Study NCT00539448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: in combination with insulin Glulisine as bolus regimen
Study NCT00539448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: in combination with insulin Glargine as bolus regimen
Study NCT03590587 — intervention group
Intervention type: DRUG
Intervention: 0.19 mg fluocinolone acetonide (FAc) implant
Description: 0.19 mg fluocinolone acetonide (FAc) implant
Study NCT03590587 — intervention group
Intervention type: DEVICE
Intervention: 0.19 mg fluocinolone acetonide (FAc) implant
Description: 0.19 mg fluocinolone acetonide (FAc) implant
Study NCT01073982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tart cultivar Montmorency cherry juice
Description: 21 ounces of experimental or placebo juice, consumed daily for 21 days.
Study NCT01073982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cultivar Montmorency cherry juice
Description: 21 ounces of experimental or placebo juice, consumed daily for 21 days.
Study NCT00433849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
Study NCT00433849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks